









Markets
/
Stocks
/
nasdaq-flgt
/

Fulgent Genetics Inc

FLGT

15.590USD

-0.780-4.76%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

271.99MMarket Cap

LossP/E TTM



Fulgent Genetics Inc

15.590

-0.780-4.76%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fulgent Genetics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Fulgent Genetics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 31 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.33.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fulgent Genetics Inc's Score

Industry at a Glance

Industry Ranking

31 / 75

Overall Ranking

171 / 4542

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Fulgent Genetics Inc Highlights

StrengthsRisks

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fairly Valued

The company’s latest PE is -7.93, at a medium 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.23K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

24.333

Target Price

+48.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Fulgent Genetics Inc is 6.28, ranking 58 out of 75 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 83.34M, representing a year-over-year increase of 9.34%, while its net profit experienced a year-over-year increase of 297.72%.

Score

Industry at a Glance

Previous score

6.28

Change



Financials

7.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.96

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.51

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Fulgent Genetics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Fulgent Genetics Inc is 8.79, ranking 4 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -7.93, which is -196.00% below the recent high of 7.61 and -505.60% above the recent low of -48.02.

Score

Industry at a Glance

Previous score

8.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 31/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Fulgent Genetics Inc is 7.33, ranking 41 out of 75 in the Healthcare Providers & Services industry. The average price target is 35.00, with a high of 36.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

24.333

Target Price

+48.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Fulgent Genetics Inc

FLGT

CVS Health Corp

CVS

Teladoc Health Inc

TDOC

HCA Healthcare Inc

HCA

Tenet Healthcare Corp

THC

Natera Inc

NTRA

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Fulgent Genetics Inc is 7.23, ranking 12 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 17.14 and the support level at 13.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.32

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

1.004

Neutral

RSI(14)

36.722

Neutral

STOCH(KDJ)(9,3,3)

59.561

Sell

ATR(14)

0.651

Low Volatility

CCI(14)

33.602

Neutral

Williams %R

46.568

Neutral

TRIX(12,20)

-1.246

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

16.260

Sell

MA10

15.789

Sell

MA20

15.092

Buy

MA50

20.943

Sell

MA100

24.234

Sell

MA200

22.663

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Fulgent Genetics Inc is 5.00, ranking 49 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 59.35%, representing a quarter-over-quarter decrease of 0.77%. The largest institutional shareholder is The Vanguard, holding a total of 1.25M shares, representing 4.02% of shares outstanding, with 4.99% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Hsieh (Ming)

8.76M

-0.06%

BlackRock Institutional Trust Company, N.A.

1.99M

+22.91%

The Vanguard Group, Inc.

Star Investors

1.17M

+1.15%

Acadian Asset Management LLC

1.14M

+1.99%

Millennium Management LLC

1.47M

+1.84%

Gao (Hanlin)

869.55K

-0.12%

Dimensional Fund Advisors, L.P.

1.13M

-0.12%

D. E. Shaw & Co., L.P.

567.77K

+19.16%

BlackRock Financial Management, Inc.

661.24K

+135.39%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fulgent Genetics Inc is 6.80, ranking 25 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Fulgent Genetics Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.